DNA Aptamer-Polymer Conjugates for Selective Targeting of Integrin α4β1⁺ T-Lineage Cancers

Area of Science:

• Biotechnology
• Oncology
• Molecular Biology

Background:

• Targeting T-cell malignancies is challenging due to T-cell lineage overlap.
• Current chemotherapy lacks specificity, leading to relapsed/refractory disease.
• Developing targeted therapies for T-cell leukemia and lymphoma is a critical unmet need.

Purpose of the Study:

• To discover and characterize a novel DNA aptamer targeting cancer cells in T-cell malignancies.
• To investigate the binding properties and therapeutic potential of the aptamer HR7A1.
• To address challenges for in vivo translation of aptamer-based therapies.

Main Methods:

• Discovery of DNA aptamer HR7A1 with high affinity for integrin α4β1 (VLA-4).
• Truncation of aptamer and assessment of binding specificity to T-lineage cancer cells versus healthy immune cells.
• Cryo-electron microscopy (cryo-EM) and competition studies to determine binding site.
• Characterization of in vivo barriers and synthesis of an aptamer-polymer conjugate.

Main Results:

• HR7A1 aptamer exhibits low nanomolar affinity for integrin α4β1 (VLA-4).
• Truncated aptamer shows selective binding to T-lineage cancer cells.
• HR7A1 binds to an overlapping site with fibronectin and VCAM-1 on α4β1, suggesting potential to sensitize cancers to chemotherapy.
• Aptamer-polymer conjugate developed to overcome barriers like serum instability and short half-life.

Conclusions:

• The DNA aptamer HR7A1 is a promising candidate for targeting T-cell malignancies.
• HR7A1's binding mechanism offers potential for sensitizing blood cancers to chemotherapy.
• The developed aptamer-polymer conjugate represents a viable strategy for in vivo aptamer-based therapies.